Supply Quality TNJONE 99% Purity Ibuprofen 15687-27-1

Product Description 

Celecoxib is a selective Cox-2(cyclooxygenase-2) inhibitor (IC50 of 40 nM). Celecoxib shows low sensitivity against Cox-1 (IC50 of 15 μM). Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 (IC50of 32.86 μM) and CNE1-LMP1 (IC50 of 61.31 μM).Celecoxib

Celecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain in adults, painful menstruation, and juvenile rheumatoid arthritis in people .

Celecoxibis a nonsteroidal anti-inflammatory drug (NSAID). It works by reducing hormones that cause inflammation and pain in the body. Celecoxib is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain.

Product Detail

Celecoxib is a selective Cox-2(cyclooxygenase-2) inhibitor (IC50 of 40 nM). Celecoxib shows low sensitivity against Cox-1 (IC50 of 15 μM). Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 (IC50of 32.86 μM) and CNE1-LMP1 (IC50 of 61.31 μM).Celecoxib

Celecoxib is a COX-2 selective nonsteroidal anti-inflammatory drug (NSAID). It is used to treat the pain and inflammation of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, acute pain in adults, painful menstruation, and juvenile rheumatoid arthritis in people .

Celecoxib is a nonsteroidal antiinflammatory drug (NSAID) first launched as Celebrex in the US for the treatment of symptoms in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). Celecoxib belongs to a new class of 1, 5-diarylpyrazoles and can be synthesized by heat-promoted heterocyclization of a trifiuoro-l,3-dione with appropriate arylhydrazine. Celecoxib is a highly selective inhibitor of COX-2, the inducible form of cyclooxygenase expressed during inflammatory processes; it does not block the constitutive form COX-1, thus suppressing the gastric and intestinal toxicity of most non-selective NSAIDs. The potency ratio COX1/COX2 on purified human enzymes was about 400. In several in vivo models of acute and chronic inflammation, Celecoxib demonstrated potent antiinflammatory activity without affecting gastric or urinary prostaglandin PGE2. In several clinical studies performed with patients suffering from osteoarthritis or rheumatoid arthritis, Celecoxib was shown to be well tolerated and to relieve pain and inflammation more efficiently compared with other standard NSAIDs; the gastrointestinal safety profile was significantly better than that of other NSAIDs. Interestingly, Celecoxib was approved for another indication in patients with familial adenomatous polyposis (FAP). A six-month clinical trial demonstrated a 28% reduction in the number of colorectal polyps with Celecoxib, compared to a 5% reduction with placebo.

Item	Standard	Result
Appearance	White or almost white crystalline powder	Almost white crystalline powder
Melting point	152-156°C	154.6-155.1°C
Specific optical rotation	-16° to -19°	-17.5°
Identification	(1)The retention time of the major peak in the chromatogram of the assay preparation corresponds to that in the chromatogram of the standard preparation,as obtained in the assay.	Complies
	(2)UV absorption Max. at 266nm.	Complies
	(3)IR spectra is consistent with CRS.	Complies
PH	4.5-6.5	5.7
Chloride	0.02% max	<0.02%
Fluorides	4.8%min	4.9%
Related substances	Individual impurity not more than 0.5%	0.35%
	Total impurities not more than 2.0%	0.76%
Water	0.5% max	0.13%
Residue on ignition	0.1%max	0.06%
Heavy metals	Less than or egual to 20 millionths	Less than20 millionths
Assay(C12H14Cl2FNO4S)	98.0%min	99.0%

Our Company Introduction 

Factory Photos 

Packing and Shipping